BioMarin : FDA Extends Review Of BLA For Roctavian Gene Therapy For Severe Hemophilia A

(RTTNews) – BioMarin Pharmaceutical Inc. (BMRN) said Monday that it received notice from the U.S. Food and Drug Administration that the agency has extended review of the company’s Biologics License Application (BLA) for Roctavian (valoctocogene roxaparvovec) gene therapy for adul

admin